1. Home
  2. CRDF

CRDF

Cardiff Oncology Inc.

Logo Cardiff Oncology Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Founded: 1999 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 262.7M IPO Year: N/A
Target Price: $10.50 AVG Volume (30 days): 1.8M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $0.94 - $6.42 Next Earning Date: 05-02-2024
Revenue: $488,000 Revenue Growth: 26.42%
Revenue Growth (this year): -49.31% Revenue Growth (next year): -72.51%

Share on Social Networks: